Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

The American Journal of Cardiology
Edouard CheneauRon Waksman

Abstract

Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

Citations

Dec 8, 2010·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Sunil X AnandPaul M Heerdt
Dec 15, 2006·The New England Journal of Medicine·Rasheed A Saad
Feb 28, 2007·Vascular Health and Risk Management·Sam J Lehman, Derek P Chew
Jul 1, 2007·Future Cardiology·Eugenia Nikolsky, Gregg W Stone
Apr 15, 2006·Cardiovascular Drug Reviews·Nicolas W Shammas
Mar 23, 2005·Pediatric Blood & Cancer·Vinod V Balasa
Feb 21, 2018·Anesthesia and Analgesia·Katherine L ZaleskiViviane G Nasr
Aug 19, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Cheuk-Kit Wong, Harvey D White
Apr 12, 2020·JACC. Clinical Electrophysiology·Aleksandr VoskoboinikEdward P Gerstenfeld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.